Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RYTM Rhythm Pharmaceuticals Inc.

休市中 07-24 16:00:00 EDT

102.10

-0.56

-0.55%

盘后102.10

+0.000.00%

19:48 EDT

最高104.87	最低101.49	成交量46.71万
今开103.92	昨收102.66	日振幅3.29%
总市值69.72亿	流通市值66.70亿	总股本6,829万
成交额4,817万	换手率0.72%	流通股本6,533万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":102.1,"timestamp":1784923200000,"preClose":102.66,"halted":0,"volume":467133,"hourTrading":{"tag":"盘后","latestPrice":102.1,"preClose":102.1,"latestTime":"19:48 EDT","volume":30015,"amount":3064533.08,"timestamp":1784936888021,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005454899668809686,"floatShares":65327260,"shares":68285039,"eps":-3.138955,"marketStatus":"休市中","change":-0.56,"latestTime":"07-24 16:00:00 EDT","open":103.92,"high":104.87,"low":101.49,"amount":48167741.95215,"amplitude":0.032924,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.138955,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":102.66,"preHourTrading":{"tag":"盘前","latestPrice":103.99,"preClose":102.66,"latestTime":"09:28 EDT","volume":380,"amount":38834.00728,"timestamp":1784899680100,"change":1.33,"changeRate":0.012955,"amplitude":0.037113},"postHourTrading":{"tag":"盘后","latestPrice":102.1,"preClose":102.1,"latestTime":"19:48 EDT","volume":30015,"amount":3064533.08,"timestamp":1784936888021,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8828938210924545,"impliedVol":0.5571,"impliedVolPercentile":0.4502},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"1170739948","title":"Rhythm Pharmaceuticals宣布《新英格兰医学杂志》发表针对获得性下丘脑肥胖症的3期Transcend试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170739948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170739948?lang=zh_cn&edition=full","pubTime":"2026-07-09 05:09","pubTimestamp":1783544956,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 宣布，其针对获得性下丘脑肥胖症的3期Transcend临床试验结果，已获国际顶尖医学期刊《新英格兰医学杂志》发表。研究聚焦于评估公司在研疗法对因下丘脑损伤导致严重肥胖患者群体的疗效与安全性。获得性下丘脑肥胖是一种罕见且严重的疾病，常由脑部肿瘤、手术或创伤对下丘脑造成损伤引发。此次在顶级期刊上公布详细数据，为后续与监管机构的沟通及潜在疗法的推进奠定了坚实的科学基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4139","BK4585","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131755559","title":"Rhythm Pharmaceuticals公布多项新数据：展示MC4R激动剂在获得性下丘脑肥胖、Bardet-Biedl综合征及Prader-Willi综合征中的研究成果于ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1131755559","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131755559?lang=zh_cn&edition=full","pubTime":"2026-06-16 04:02","pubTimestamp":1781553736,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 宣布，将在ENDO 2026大会上展示其MC4R激动剂针对获得性下丘脑肥胖、Bardet-Biedl综合征以及Prader-Willi综合征的多项最新研究数据。这些报告将揭示该疗法在多种罕见遗传性肥胖疾病中的最新进展与潜在疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RYTM","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183006967","title":"Rhythm Pharmaceuticals六个月数据显示Setmelanotide显著改善普瑞德-威利综合征多项指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1183006967","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183006967?lang=zh_cn&edition=full","pubTime":"2026-06-13 20:03","pubTimestamp":1781352198,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 于2026年5月7日公布的最新六个月临床数据显示，其核心药物Setmelanotide在治疗普瑞德-威利综合征方面展现出积极疗效，显著改善了多项关键临床终点。\n该数据进一步证实了Setmelanotide在控制与PWS相关的严重饥饿感和体重管理方面的潜力。研究结果显示，接受治疗的患者在多个评估维度上均获得了具有统计学意义和临床意义的改善。\n这些积极结果加强了该药物作为PWS患者潜在重要治疗选择的地位，为后续的监管申请和临床开发路径提供了关键支持。公司将持续推进相关研究，以期为这一罕见病患者群体带来新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RYTM","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114862762","title":"Rhythm Pharmaceuticals 将公布评估 Setmelanotide 在普瑞德-威利综合征患者中的六个月中期二期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1114862762","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114862762?lang=zh_cn&edition=full","pubTime":"2026-06-13 04:02","pubTimestamp":1781294534,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 即将公布其药物 Setmelanotide 用于治疗普瑞德-威利综合征患者的二期临床试验中期结果。此次公布的数据将涵盖为期六个月的研究阶段。\n该消息备受市场关注，因 Setmelanotide 的疗效数据可能对公司的未来前景产生重要影响。投资者正密切关注试验结果，以评估该疗法在应对这一罕见遗传性疾病方面的潜力与进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143456364","title":"异动解读 | 第一季度营收增长超预期，Rhythm Pharmaceuticals盘中大涨12.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143456364","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143456364?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:52","pubTimestamp":1777989161,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) 今日盘中股价大幅上涨12.79%，表现强劲。消息面上，公司公布了第一季度财务业绩，显示产品收入达到6010万美元，较去年同期的3270万美元实现显著增长。营收增长主要得益于其针对获得性下丘脑肥胖症的药物IMCIVREE的上市销售。此外，公司第一季度净亏损为5560万美元，基本符合分析师预期。市场对该业绩反应积极。根据LSEG数据，在覆盖该股的16家券商中，有15家给予“买入”或更高评级，目标价中位数为140美元，显示出分析师对公司未来前景的看好。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177130155","title":"Rhythm Pharmaceuticals宣布Imcivree®（司美兰肽）获欧盟委员会授予上市许可，用于治疗获得性下丘脑性肥胖患者的肥胖及饥饿控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1177130155","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177130155?lang=zh_cn&edition=full","pubTime":"2026-05-01 18:56","pubTimestamp":1777632976,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) 近日宣布，其创新药物Imcivree®（活性成分：司美兰肽）已正式获得欧盟委员会颁发的上市许可。该批准标志着该药物可用于治疗获得性下丘脑性肥胖症患者的肥胖问题及饥饿控制。\n此次授权为患有该罕见疾病的患者提供了新的治疗选择，有望改善其生活质量。公司表示将继续推进相关临床工作，确保药物可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187320249","title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增38.35%，机构多头占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1187320249","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187320249?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:04","pubTimestamp":1777349073,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.将于2026年05月05日发布最新季度财报，市场聚焦营收增速与适应症扩展后的放量节奏。市场一致预期本季度Rhythm Pharmaceuticals Inc.营收为5,577.64万，同比增长38.35%；调整后每股收益为-0.85元，同比下降21.52%；公司未披露针对本季度的毛利率与净利润或净利率指引。当前发展前景最大的现有业务为Imcivree在获得“获得性下丘脑性肥胖”适应症后带来的放量潜力，上一季度公司总收入为5,725.30万，同比增长36.87%，为后续扩张提供基数与验证。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增38.35%，机构多头占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165778480","title":"Rhythm Pharmaceuticals获欧盟CHMP积极意见：Imcivree®（Setmelanotide）有望用于治疗下丘脑损伤所致获得性肥胖及饥饿控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1165778480","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165778480?lang=zh_cn&edition=full","pubTime":"2026-03-26 21:03","pubTimestamp":1774530213,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.（RYTM）宣布，其药物Imcivree®（Setmelanotide）获得了欧洲药品管理局人用医药产品委员会（CHMP）的积极评价。该药物拟用于因下丘脑损伤或功能障碍导致的获得性下丘脑肥胖症患者的肥胖治疗及饥饿控制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RYTM","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137824294","title":"FDA批准脑损伤相关肥胖疗法后，Rhythm制药公司盘前股价上涨7.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137824294","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137824294?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:30","pubTimestamp":1774002618,"startTime":"0","endTime":"0","summary":"在获得美国食品药品监督管理局（FDA）对其脑损伤相关肥胖治疗方案的批准后，Rhythm Pharmaceuticals Inc.（RYTM）股价在盘前交易时段强势攀升7.4%。这一监管层面的重大突破，为该公司针对下丘脑肥胖症的治疗产品扫清了上市障碍，显著提振了投资者信心，并直接反映在股价的积极走势上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RYTM","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100389039","title":"Rhythm Pharmaceuticals宣布Imcivree®（Setmelanotide）获FDA批准用于治疗获得性下丘脑性肥胖患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1100389039","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100389039?lang=zh_cn&edition=full","pubTime":"2026-03-20 06:30","pubTimestamp":1773959411,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) 近日宣布，其药物Imcivree®（活性成分：Setmelanotide）已获得美国食品药品监督管理局（FDA）的正式批准，适用于治疗获得性下丘脑性肥胖患者。这一重要监管里程碑为患有该罕见代谢疾病的患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RYTM","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189195604","title":"Rhythm制药高管称2022年启动的试验受GLP-1药物热潮冲击，或致患者脱落率攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=1189195604","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189195604?lang=zh_cn&edition=full","pubTime":"2026-03-17 05:01","pubTimestamp":1773694879,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.（简称Rhythm制药）管理层透露，该公司于2022年启动的临床试验项目遭遇外部环境变化。随着GLP-1类药物在代谢疾病治疗领域迅速崛起，可能对试验进程产生干扰，进而推高了受试者的中途退出比例。\n这一动向折射出创新药研发生态的复杂性与动态性。当同类疗法出现突破性进展时，既存临床试验的推进策略需及时调整，以应对患者偏好变化带来的挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160418964","title":"Rhythm制药高管称：多数安慰剂组患者主动停药，而多数Setmelanotide组患者因副作用中止治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1160418964","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160418964?lang=zh_cn&edition=full","pubTime":"2026-03-17 04:50","pubTimestamp":1773694215,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.高管披露的最新数据显示，临床试验中服用安慰剂的患者多数是自主选择终止治疗，而接受Setmelanotide药物治疗的患者则主要因不良反应退出研究。\n这一对比凸显了不同治疗路径下的患者决策差异。自主停药往往反映患者对疗效的评估或个人考量，而药物相关中止则指向耐受性问题。Setmelanotide作为针对罕见肥胖症的研究性疗法，其安全性表现正受到密切关注。\n值得注意的是，两组停药动因的差异可能影响对药物有效性的解读。主动停药可能暗示疗效未达预期，而副作用导致的退出则更直接关联药物特性。此类细节对评估实验结果的可靠性具有重要参考价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142586774","title":"Rhythm制药高管电话会透露：Emanate试验各组患者退出率平均达40%至60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142586774","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142586774?lang=zh_cn&edition=full","pubTime":"2026-03-17 04:48","pubTimestamp":1773694130,"startTime":"0","endTime":"0","summary":"在最新电话会议中，Rhythm Pharmaceuticals Inc.高管披露，其Emanate临床试验出现显著患者流失现象。数据显示，所有试验组别的受试者退出比率介于40%到60%之间，平均退出率持续处于这一高位区间。\n这一患者脱落情况引发对试验设计及药物耐受性的关注。行业观察人士指出，如此规模的退出率可能影响试验数据的完整性和最终结果的可信度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103241062","title":"Rhythm制药公司公布Emanate三期试验未达主要终点 盘后股价重挫约13%至78.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103241062","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103241062?lang=zh_cn&edition=full","pubTime":"2026-03-17 04:05","pubTimestamp":1773691511,"startTime":"0","endTime":"0","summary":"在宣布其Emanate三期临床试验未能达到主要终点后，Rhythm制药公司股价在盘后交易时段遭遇大幅抛售，跌幅约达13%，最终收报78.58美元。\n这一临床试验结果的公布，直接引发了投资者对公司核心产品前景的担忧，导致股价应声下跌。市场普遍将此次试验结果视为公司研发管线推进过程中的一次挫折。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126839750","title":"Rhythm Pharmaceuticals Inc. 计划持续推进Emanate数据集分析并评估未来临床开发路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1126839750","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126839750?lang=zh_cn&edition=full","pubTime":"2026-03-17 04:02","pubTimestamp":1773691334,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 宣布，公司计划继续深入分析Emanate数据集，并在此基础上评估潜在的未来临床开发路径。这一举措旨在充分挖掘现有数据的价值，为后续研发决策提供科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103242371","title":"Rhythm Pharmaceuticals公布Setmelanotide治疗获得性下丘脑性肥胖三期Transcend试验新增积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1103242371","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103242371?lang=zh_cn&edition=full","pubTime":"2026-03-02 01:31","pubTimestamp":1772386277,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) 近日宣布，其针对获得性下丘脑性肥胖患者开展的setmelanotide药物三期Transcend临床试验获得更多积极数据。该结果进一步验证了该疗法在目标人群中的潜在疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173730041","title":"异动解读 | 分析师下调目标价，Rhythm Pharmaceuticals盘中大跌5.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173730041","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173730041?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:02","pubTimestamp":1772204531,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.  今日盘中股价大幅下挫5.30%，引起了市场的关注。消息面上，多家华尔街分析师在周五下调了该公司的目标价。Needham将Rhythm Pharmaceuticals的目标价从148美元下调至139美元。分析师下调目标价通常反映了对公司未来盈利前景或估值的重新评估，这可能是导致股价承压下跌的主要原因。尽管这些调整并未涉及股票评级的直接下调，但目标价的降低向市场传递了更为谨慎的信号，影响了投资者的短期情绪和交易决策，从而在盘中引发了显著的抛售压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139719460","title":"Rhythm制药公司宣布股东增售240万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1139719460","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139719460?lang=zh_cn&edition=full","pubTime":"2026-02-27 06:40","pubTimestamp":1772145615,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.（简称：Rhythm制药）近日披露，公司部分持股股东计划进一步出售最高达240万股普通股。此次售股计划由现有股东主导，旨在实现其个人资产配置目标。\n该交易预计将为市场提供额外的流动性，同时可能对现有股权结构产生一定影响。公司强调，此次售股行为属于股东个人财务安排，不涉及公司新发行股份，因此不会对Rhythm制药的资本总额产生稀释效应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613456392","title":"Rhythm Pharmaceuticals, Inc.跌4.23% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2613456392","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613456392?lang=zh_cn&edition=full","pubTime":"2026-02-20 22:58","pubTimestamp":1771599518,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日22时58分，Rhythm Pharmaceuticals, Inc.股票出现波动，股价急速下挫4.23%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Cardio Diagnostics Holdings Inc.、Briacell Therapeutics Corp C/Wts 、Impact Biomedical, Inc.涨幅较大，Cardio Diagnostics Holdings Inc.、Cdt Equity Inc.、Moolec Science Sa较为活跃，换手率分别为2422.84%、429.23%、59.11%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Cdt Equity Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为48.11%、35.46%、35.40%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022022583897a6948e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022022583897a6948e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","RYTM","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112874946","title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增45.45%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1112874946","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112874946?lang=zh_cn&edition=full","pubTime":"2026-02-19 11:59","pubTimestamp":1771473592,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.将于2026年02月26日美股盘前发布最新季度财报，市场关注营收与盈利改善节奏及研发推进对后续收入的带动效应。市场一致预期显示，本季度Rhythm Pharmaceuticals Inc.营收预计为5,597.35万美元，同比增长45.45%；调整后每股收益预计为-0.81美元，同比下降13.40%；息税前利润预计为-5,310.43万美元，同比下降27.38%。本季度市场普遍预计Rhythm Pharmaceuticals Inc.营收继续增长至5,597.35万美元，同比提升45.45%，主要依据上季度强势的5,129.80万美元营收基础及渠道与支付端延续改善的趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增45.45%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":-0.0422},{"period":"1month","weight":-0.0507},{"period":"3month","weight":0.1914},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.1699},{"period":"ytd","weight":-0.0462}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rhythm Pharmaceuticals, Inc.是一家特拉华州的公司，成立于2013年2月。该公司是一家全球性、商业阶段的生物制药公司，致力于改变患有罕见神经内分泌疾病的患者及其家人的生活。该公司专注于推进黑皮质素-4受体激动剂，包括他们的主要资产IMCIVREE，作为一种精准药物，旨在治疗由罕见的MC4R通路疾病引起的食欲亢进和严重肥胖。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.048958},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.056668},{"month":4,"riseRate":0.555556,"avgChangeRate":0.013671},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045608},{"month":6,"riseRate":0.555556,"avgChangeRate":0.069919},{"month":7,"riseRate":0.444444,"avgChangeRate":0.241489},{"month":8,"riseRate":0.75,"avgChangeRate":0.239414},{"month":9,"riseRate":0.375,"avgChangeRate":-0.040591},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}